ArticleStem cell research & therapy2025
Adipose-derived mesenchymal stem cell therapy modulates mitochondrial function to attenuate acetaminophen-induced liver injury by DDIT4/PGC-1α axis.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcetaminophen (APAP) overdose is a leading cause of drug-induced liver injury, with limited treatment options. Mitochondrial dysfunction plays a central role in the pathogenesis of APAP-induced liver injury (AILI). Mitochondrial damage induces cell death, liver necrosis, and sever inflammation, leading to irreversible liver failure. Therefore, it is urgent to develop alternative treatments. Mesenchymal stem cell (MSC)-based cell therapy recently has received increasing attention for its role in regulating mitochondrial function.
objectiveThis study aimed to investigate the regulation of mitochondrial function and the therapeutic potential of MSCs in treating AILI and underlying mechanisms.
methodsAILI mouse model was established by injection of overdosed APAP. Mice were treated with adipose-derived MSCs (AMSCs) via the tail vein. The blood and liver tissues were collected for assessment of liver necrosis and mitochondrial function. To further verify the mechanism, hepatocyte-specific DNA damage-inducible transcript 4 (DDIT4) knockout (Ddit4
resultsWe showed that AMSCs treatment significantly reduced liver necrosis, oxidative stress, and mitochondrial dysfunction in AILI. DDIT4 expression in hepatocytes was identified as playing an important part in AMSCs treating AILI by using RNA-Seq and histological analysis. DDIT4 upregulation in liver samples of AILI patients characterized by snRNA-Seq and spatial transcriptomics analysis, which indicates DDIT4 plays a role in AILI. Ddit4
conclusionsIn summary, this study indicates the potential role of stem cell therapy in modulating mitochondrial function and highlights the role of activation the DDIT4/PGC-1α pathway in protecting hepatic mitochondria to alleviate AILI. This study provides a new mechanistic perspective for stem cell therapy in the treatment of AILI and potential targets for clinical drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.